ADAM10 and lymphoma: In contrast to our study, ADAM10 single KD was sufficient to inhibit nasopharyngeal cancer migration [60], and treatment with a monoclonal antibody against ADAM10 inhibited lymphoma growth in a xenograft model and gastrointestinal tumor growth in a genetic mouse model [70].